Annovis Bio (ANVS) Competitors $2.42 +0.06 (+2.54%) As of 09:43 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANVS vs. ALXO, LFVN, ACRS, NVCT, NLTX, MOLN, TIL, BIOA, CGEN, and ALECShould you be buying Annovis Bio stock or one of its competitors? The main competitors of Annovis Bio include ALX Oncology (ALXO), Lifevantage (LFVN), Aclaris Therapeutics (ACRS), Nuvectis Pharma (NVCT), Neoleukin Therapeutics (NLTX), Molecular Partners (MOLN), Instil Bio (TIL), BioAge Labs (BIOA), Compugen (CGEN), and Alector (ALEC). These companies are all part of the "pharmaceutical products" industry. Annovis Bio vs. Its Competitors ALX Oncology Lifevantage Aclaris Therapeutics Nuvectis Pharma Neoleukin Therapeutics Molecular Partners Instil Bio BioAge Labs Compugen Alector ALX Oncology (NASDAQ:ALXO) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation. Do analysts prefer ALXO or ANVS? ALX Oncology currently has a consensus target price of $3.30, indicating a potential upside of 622.10%. Annovis Bio has a consensus target price of $18.00, indicating a potential upside of 643.80%. Given Annovis Bio's stronger consensus rating and higher probable upside, analysts clearly believe Annovis Bio is more favorable than ALX Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALX Oncology 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71Annovis Bio 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the media prefer ALXO or ANVS? In the previous week, ALX Oncology and ALX Oncology both had 1 articles in the media. Annovis Bio's average media sentiment score of 0.00 beat ALX Oncology's score of -1.00 indicating that Annovis Bio is being referred to more favorably in the news media. Company Overall Sentiment ALX Oncology Negative Annovis Bio Neutral Do institutionals & insiders believe in ALXO or ANVS? 98.0% of ALX Oncology shares are held by institutional investors. Comparatively, 15.8% of Annovis Bio shares are held by institutional investors. 21.0% of ALX Oncology shares are held by company insiders. Comparatively, 20.8% of Annovis Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has higher valuation & earnings, ALXO or ANVS? Annovis Bio is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioALX OncologyN/AN/A-$134.85M-$2.47-0.19Annovis BioN/AN/A-$24.59M-$2.16-1.12 Which has more volatility & risk, ALXO or ANVS? ALX Oncology has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, Annovis Bio has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500. Is ALXO or ANVS more profitable? ALX Oncology's return on equity of -104.43% beat Annovis Bio's return on equity.Company Net Margins Return on Equity Return on Assets ALX OncologyN/A -104.43% -77.74% Annovis Bio N/A -300.56%-193.50% SummaryAnnovis Bio beats ALX Oncology on 7 of the 13 factors compared between the two stocks. Get Annovis Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANVS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANVS vs. The Competition Export to ExcelMetricAnnovis BioMED IndustryMedical SectorNYSE ExchangeMarket Cap$46.29M$2.91B$5.51B$20.71BDividend YieldN/A2.44%5.24%3.72%P/E Ratio-1.1020.4427.2127.82Price / SalesN/A190.28370.4747.03Price / CashN/A41.7026.2118.22Price / Book3.617.397.944.59Net Income-$24.59M-$55.04M$3.17B$982.91M7 Day Performance3.42%2.51%1.79%0.65%1 Month Performance-24.33%-0.21%1.27%4.26%1 Year Performance-84.31%3.41%33.56%13.93% Annovis Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANVSAnnovis Bio1.4872 of 5 stars$2.42+2.5%$18.00+643.8%-78.5%$46.29MN/A-1.103ALXOALX Oncology2.6462 of 5 stars$0.42+2.3%$3.30+695.0%-91.9%$21.67MN/A0.0040Negative NewsGap UpLFVNLifevantage4.2787 of 5 stars$13.08+3.1%$30.50+133.2%+128.4%$159.74M$200.16M18.96260News CoverageACRSAclaris Therapeutics2.6215 of 5 stars$1.42-3.4%$9.71+584.1%+21.7%$159.17M$18.72M-1.02100Gap UpNVCTNuvectis Pharma2.3228 of 5 stars$7.47-1.1%$17.00+127.6%+27.0%$157.75MN/A0.008NLTXNeoleukin TherapeuticsN/A$16.16-2.5%N/A-41.1%$151.87MN/A-5.2090High Trading VolumeMOLNMolecular Partners2.9581 of 5 stars$3.79+0.8%$12.00+216.6%-44.7%$151.81M$5.65M0.00180TILInstil Bio3.1247 of 5 stars$20.83-9.3%$119.00+471.3%+139.0%$150.66MN/A-1.74410BIOABioAge LabsN/A$4.13-1.7%N/AN/A$150.57MN/A0.00N/ACGENCompugen1.5411 of 5 stars$1.78+7.2%$4.00+124.7%+10.3%$148.13M$27.86M-11.1370Gap UpALECAlector3.8007 of 5 stars$1.40-5.4%$4.00+185.7%-67.2%$147.99M$100.56M-1.11270 Related Companies and Tools Related Companies ALX Oncology Competitors Lifevantage Competitors Aclaris Therapeutics Competitors Nuvectis Pharma Competitors Neoleukin Therapeutics Competitors Molecular Partners Competitors Instil Bio Competitors BioAge Labs Competitors Compugen Competitors Alector Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ANVS) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annovis Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Annovis Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANVS Stock Alerts